RSMV - ETF AI Analysis
Top Page
Relative Strength Managed Volatility Strategy ETF 1Shs (RSMV)
RSMV is an ETF whose rating suggests it offers a solid but not outstanding mix of quality and risk. Strong holdings like Merck, Apple, and Exxon Mobil support the fund’s profile through robust financial performance, attractive growth prospects, and strategic initiatives, while diversified exposure across sectors helps balance risk. However, names such as Philip Morris and AbbVie introduce concerns around leverage and financial stability, and the relatively large position in the unnamed top holding increases concentration risk that can make the fund more sensitive to issues in that single stock.
RSMV vs. SPDR S&P 500 ETF (SPY)
- AUM
- N/A
- Region
- North America
- Expense Ratio
- 0.95%
- Beta
- 0.68
- Issuer
- Teucrium
- Inception Date
- Jan 13, 2025
- Dividend Yield
- 0.98%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
RSMV Summary
RSMV is an actively managed ETF that follows a “managed volatility” growth theme across the total U.S. stock market, rather than tracking a single index. It looks for companies showing strong recent performance while trying to smooth out big ups and downs. The fund holds many well-known names such as Merck, Eli Lilly, Coca-Cola, IBM, and Johnson & Johnson, and spreads investments across sectors like financials, technology, and health care. Someone might consider RSMV for long-term growth with some built-in risk control, but it can still go up and down with the stock market and charges a relatively high fee.
How much will it cost me?
The Relative Strength Managed Volatility Strategy ETF (RSMV) has an expense ratio of 0.95%, which means you’ll pay $9.50 per year for every $1,000 invested. This is higher than average because it’s actively managed, meaning the fund managers are making strategic decisions to optimize growth and manage risk rather than simply tracking a market index.
What would affect this ETF?
The RSMV ETF, with strong exposure to sectors like Technology and Health Care, could benefit from continued innovation and consumer demand in these areas, as well as a stable U.S. economy. However, it may face challenges if interest rates rise, potentially impacting growth-focused companies, or if regulatory changes affect key holdings like Apple and Adobe. Additionally, market volatility could influence performance despite the fund's managed volatility strategy.
RSMV Top 10 Holdings
RSMV is leaning heavily into U.S. large caps, with a clear tilt toward tech and health care names that are doing most of the heavy lifting. Microsoft, Apple, and Meta are all rising on the back of cloud, devices, and digital ads, giving the fund a strong Big Tech engine. Dell and Palantir add more AI-flavored momentum, though their ride has been a bit more mixed. On the defensive side, Merck and Johnson & Johnson are steady but not spectacular, while JPMorgan has recently lagged, acting as a mild brake on performance.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MA | Mastercard | 4.99% | $913.88K | $543.49B | 10.83% | 75Outperform |
 XOM | Exxon Mobil | 4.92% | $901.75K | $731.34B | 55.37% | 74Outperform |
 CVX | Chevron | 4.96% | $909.16K | $445.95B | 45.71% | 71Outperform |
 KO | Coca-Cola | 4.96% | $909.19K | $402.25B | 34.64% | 75Outperform |
 PM | Philip Morris | 4.83% | $885.36K | $311.57B | 28.61% | 61Neutral |
 ABBV | AbbVie | 5.00% | $916.38K | $510.84B | 24.71% | 66Neutral |
 MRK | Merck & Company | 5.00% | $917.24K | $365.88B | 68.06% | 80Outperform |
 AAPL | Apple | 4.91% | $899.34K | $4.95T | 34.73% | 79Outperform |
 TMO | Thermo Fisher | 4.94% | $905.95K | $254.15B | 19.28% | 72Outperform |
RSMV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For RSMV, the sentiment is Negative. The current price of 28.04 is below the 20-day moving average (MA) of 28.68, below the 50-day MA of 28.81, and below the 200-day MA of 28.28, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 38.23 is Neutral, neither overbought nor oversold. The STOCH value of 17.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RSMV.
RSMV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| RSMV | $28.04 | $31.00(10.54% Upside) | ― | 0.95% | 60Neutral |
 CGGR | $46.17 | $60.65(31.37% Upside) | $26.08B | 0.39% | 68Neutral |
 WINN | $33.48 | $43.83(30.90% Upside) | $1.22B | 0.57% | 73Outperform |
 LSGR | $45.13 | $58.43(29.48% Upside) | $891.06M | 0.59% | 75Outperform |
 PFRX | $32.91 | $41.84(27.13% Upside) | ― | 0.35% | 71Outperform |
 OAKL | $27.16 | $29.56(8.83% Upside) | ― | 0.59% | 72Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RSMV | Relative Strength Managed Volatility Strategy ETF 1Shs | 28.04 | 1.11 | 4.11% | |
| CGGR | Capital Group Growth ETF | 46.17 | 1.31 | 2.92% | |
| WINN | Harbor Long-Term Growers ETF | 33.48 | 1.72 | 5.42% | |
| LSGR | Natixis Loomis Sayles Focused Growth ETF | 45.13 | 0.07 | 0.15% | |
| PFRX | Putnam Focused U.S. Research ETF | 32.91 | -0.10 | -0.30% | |
| OAKL | Oakmark U.S. Concentrated ETF | 27.16 | 2.08 | 8.29% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.